Subcellular Performance of Nanoparticles in Cancer Therapy
Chen-Guang Liu, 1, 2,* Ya-Hui Han, 1, 2,* Ranjith Kumar Kankala, 1–3 Shi-Bin Wang, 1–3 Ai-Zheng Chen 1–3 1Institute of Biomaterials and Tissue Engineering, Huaqiao University, Xiamen, Fujian 361021, People’s Republic of China; 2College of Chemical Engineerin...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/1b5032037a514eeea4a5e354d69c2213 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Chen-Guang Liu, 1, 2,* Ya-Hui Han, 1, 2,* Ranjith Kumar Kankala, 1–3 Shi-Bin Wang, 1–3 Ai-Zheng Chen 1–3 1Institute of Biomaterials and Tissue Engineering, Huaqiao University, Xiamen, Fujian 361021, People’s Republic of China; 2College of Chemical Engineering, Huaqiao University, Xiamen, Fujian 361021, People’s Republic of China; 3Fujian Provincial Key Laboratory of Biochemical Technology (Huaqiao University), Xiamen, Fujian 361021, People’s Republic of China*These authors contributed equally to this workCorrespondence: Ranjith Kumar Kankala Email ranjithkankala@hqu.edu.cnAi-Zheng Chen Tel/Fax +86 592 616 2326Email azchen@hqu.edu.cnAbstract: With the advent of nanotechnology, various modes of traditional treatment strategies have been transformed extensively owing to the advantageous morphological, physiochemical, and functional attributes of nano-sized materials, which are of particular interest in diverse biomedical applications, such as diagnostics, sensing, imaging, and drug delivery. Despite their success in delivering therapeutic agents, several traditional nanocarriers often end up with deprived selectivity and undesired therapeutic outcome, which significantly limit their clinical applicability. Further advancements in terms of improved selectivity to exhibit desired therapeutic outcome toward ablating cancer cells have been predominantly made focusing on the precise entry of nanoparticles into tumor cells via targeting ligands, and subsequent delivery of therapeutic cargo in response to specific biological or external stimuli. However, there is enough room intracellularly, where diverse small-sized nanomaterials can accumulate and significantly exert potentially specific mechanisms of antitumor effects toward activation of precise cancer cell death pathways that can be explored. In this review, we aim to summarize the intracellular pathways of nanoparticles, highlighting the principles and state of their destructive effects in the subcellular structures as well as the current limitations of conventional therapeutic approaches. Next, we give an overview of subcellular performances and the fate of internalized nanoparticles under various organelle circumstances, particularly endosome or lysosome, mitochondria, nucleus, endoplasmic reticulum, and Golgi apparatus, by comprehensively emphasizing the unique mechanisms with a series of interesting reports. Moreover, intracellular transformation of the internalized nanoparticles, prominent outcome and potential affluence of these interdependent subcellular components in cancer therapy are emphasized. Finally, we conclude with perspectives with a focus on the contemporary challenges in their clinical applicability.Keywords: organelle, proton sponge effect, intracellular pathways, cancer therapy, nanocomposites |
|---|